Back to Interventions
Substance / Medication

Pexidartinib

SNOMED 789180004UMLS C4287804

Overview

Active Ingredient
pexidartinib
RxNorm CUI
2183102

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Fibrous histiocytoma of tendon sheath

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Recent Trials

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704Phase 4Completed32 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner Brooke, Good Logan, Quiroga Dionisia et al. · Drug Des Devel Ther · 2020
PMID: 32440095Meta-AnalysisFull text (PMC)
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.
Wagner Andrew J, Tap William D, Bauer Sebastian et al. · Oncologist · 2025
PMID: 40613752RCTFull text (PMC)
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Rugo Hope S, Campbell Mike, Yau Christina et al. · Breast Cancer Res Treat · 2025
PMID: 39625569RCTFull text (PMC)
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
Healey John H, Tap William D, Gelhorn Heather L et al. · Clin Orthop Relat Res · 2023
PMID: 36001000RCTFull text (PMC)
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
Desai Jayesh, Wagner Andrew J, Carrasco Garcia Irene et al. · Cancer · 2025
PMID: 39533157ObservationalFull text (PMC)
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor.
Dai Dong, Tecson Kristen, Pan Irene et al. · Future Oncol · 2025
PMID: 40616288ObservationalFull text (PMC)
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Tap William D, Singh Arun S, Anthony Stephen Patrick et al. · Clin Cancer Res · 2022
PMID: 34716196ObservationalFull text (PMC)
Use of neoadjuvant pexidartinib with limb salvage surgery for diffuse tenosynovial giant cell tumor: A case report.
Geiger Erik J, Jensen Andrew R, Singh Arun S et al. · J Orthop Sci · 2024
PMID: 36402606Case Report
Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor.
Bernthal Nicholas M, Randall R Lor, Zeitlinger Lauren N et al. · Case Rep Orthop · 2022
PMID: 36510622Case ReportFull text (PMC)
Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease.
Abeykoon Jithma P, Lasho Terra L, Dasari Surendra et al. · Am J Hematol · 2022
PMID: 34978715Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pexidartinib (substance)
SNOMED CT
789180004
UMLS CUI
C4287804
RxNorm CUI
2183102

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.